Home › Cases › Phaeochromocytoma Crisis
Addisonian Crisis
Phaeochromocytoma Crisis
6 questions
Question 1 · Phaeochromocytoma crisis
Correct answer: Phaeochromocytoma — classic triad of episodic headache, sweating, palpitations + paroxysmal hypertension + adrenal mass
Why
Phaeochromocytoma classic triad:
- Episodic headache, sweating, palpitations
- Paroxysmal hypertension
- 5 Ps: pressure (hypertension), pain (headache), perspiration, palpitations, pallor
- “10% rule” is outdated: ~30% are hereditary — offer genetic testing
- Often misdiagnosed as anxiety, panic attacks, or essential hypertension
Key point
Phaeochromocytoma: episodic headache + sweating + palpitations + paroxysmal hypertension. 5 Ps. ~30% hereditary.
Question 2 · Biochemical diagnosis
Correct answer: Plasma free metanephrines OR 24-hour urinary fractionated metanephrines, with appropriate collection and interpretation
Why
First-line: plasma free metanephrines (supine sampling) or 24 h urinary fractionated metanephrines. Drugs (e.g. tricyclics, labetalol) can cause false positives. Positive → endocrinology. Catecholamines and chromogranin A are not first-line.
Key point
Plasma free or urinary fractionated metanephrines; positives to endocrinology.
Question 3 · Pre-operative alpha-blockade
Correct answer: Alpha-blocker first (phenoxybenzamine or doxazosin) for 10-14 days. Then beta-blocker ONLY after alpha-blockade established. High sodium diet + fluid loading to expand contracted volume
Why
Phaeochromocytoma pre-op: ALPHA-BLOCKER FIRST (phenoxybenzamine or doxazosin) x10-14 days.
- Never start beta-blocker before alpha-blocker — unopposed alpha-stimulation from catecholamines → hypertensive crisis
- Once alpha-blocked: add beta-blocker if needed (tachycardia)
- Salt/fluid loading: tumour causes volume contraction, alpha-blockade vasodilates further
Key point
Phaeochromocytoma pre-op: alpha-blocker FIRST (10-14 days), then add beta-blocker. Never beta-blocker first — hypertensive crisis.
Question 4 · Intraoperative crisis
Correct answer: IV phentolamine (alpha-blocker) or IV sodium nitroprusside for hypertensive emergency during tumour manipulation
Why
Intraoperative phaeochromocytoma: tumour manipulation → catecholamine surge → hypertensive crisis.
- Treatment: IV phentolamine (alpha-blocker) or IV sodium nitroprusside (vasodilator)
- Anaesthetic management: continuous arterial line, avoid drugs that cause catecholamine release (suxamethonium, morphine)
- After ligation of venous drainage: hypotension expected → prepare vasopressors
Key point
Intraoperative phaeo: IV phentolamine or nitroprusside for hypertensive crisis. After vessel ligation → expect hypotension.
Question 5 · Familial syndromes
Correct answer: All phaeochromocytoma patients should be offered genetic testing — up to 30% are hereditary (MEN2, VHL, NF1, SDH mutations)
Why
Familial phaeochromocytoma: 30% have germline mutation.
- MEN2 (RET): phaeochromocytoma + medullary thyroid carcinoma; MEN2A may include hyperparathyroidism, whereas MEN2B has mucosal neuromas/marfanoid features
- VHL disease (phaeochromocytoma + clear cell RCC + haemangioblastoma)
- NF1 (neurofibromatosis)
- SDH mutations (hereditary paraganglioma-phaeochromocytoma syndromes)
- Genetic testing offered to all patients
Key point
Phaeochromocytoma: 30% hereditary. Test for MEN2 (RET), VHL, NF1, SDH. Offer genetic testing to all patients.
Question 6 · Long-term follow-up
Correct answer: Annual plasma/urinary metanephrines for at least 10 years; lifelong annual review for high-risk patients, including young/genetic/large-tumour or paraganglioma groups
Why
Phaeochromocytoma surveillance:
- Annual plasma free metanephrines (or 24h urine) for at least 10 years — 10% recurrence rate
- High-risk patients: lifelong annual surveillance, including young age, genetic disease, large tumour or paraganglioma (ESE2016)
- Malignant phaeochromocytoma (metastases): 5-year survival 50-75%
- Follow-up also for associated syndromes (MEN2: thyroid cancer, parathyroid; VHL: RCC, eye)
- Biochemistry first-line for recurrence detection
Key point
Annual metanephrines for at least 10 years. High-risk patients need lifelong annual follow-up; agree the plan with the specialist team.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.